膀胱尿路上皮癌围术期的免疫治疗进展

Advances in perioperative immunotherapy for urothelial carcinoma of the bladder

尿路上皮癌是常见的泌尿系统恶性肿瘤,其中以膀胱癌最常见,治疗方式主要有手术治疗、灌注治疗、全身化疗、局部放疗等,但肿瘤复发率仍较高。近年来,新型免疫治疗包括单药免疫治疗、双免疫联合治疗、免疫联合化疗及靶向治疗等方案,为尿路上皮癌围术期的治疗提供了新思路。该文主要综述了上述各种免疫治疗方案在尿路上皮癌围术期中应用的研究进展,以期为尿路上皮癌患者围术期的个体化治疗提供新的选择,使患者获得最大的生存获益。

Urothelial carcinoma is a common malignant tumor of the urinary system,especially bladder cancer.The main treatment methods include surgical treatment,perfusion therapy,systemic chemotherapy,local radiotherapy,but the recurrence rate of tumor is still high.In recent years,new immunotherapies including immunotherapy,double-immunotherapy,immune combined chemotherapy and targeted therapy have provided a new idea for perioperative treatment of urothelial carcinoma.This article mainly reviews the research progress of the above immunotherapy programs in the perioperative application of urothelial cancer,to provide a new option for the individualized treatment of urothelial carcinoma patients during the perioperative period,so as to maximize the survival benefits of patients.